Scancell (LON:SCLP) Hits New 12-Month Low – Should You Sell?

Scancell Holdings plc (LON:SCLP)’s share price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as GBX 8.53 ($0.11) and last traded at GBX 8.53 ($0.11), with a volume of 153344 shares changing hands. The stock had previously closed at GBX 8.90 ($0.11).

Scancell Stock Down 5.1 %

The company has a market capitalization of £85.97 million, a P/E ratio of -12.73 and a beta of 0.35. The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42. The firm’s fifty day moving average is GBX 9.80 and its 200-day moving average is GBX 13.09.

Scancell (LON:SCLP) last announced its quarterly earnings results on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share (EPS) for the quarter. As a group, equities research analysts predict that Scancell Holdings plc will post -2.5361112 EPS for the current year.

Scancell Company Profile

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.